Cargando…

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors

PURPOSE: Adjuvant endocrine therapy reduces the recurrence and mortality of early hormone receptor-positive breast cancer in both pre- and postmenopausal women. The aim of this study was to investigate adjuvant tamoxifen adherence and associated factors in breast cancer survivors. METHODS: This desc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uslu, Yasemin, Kocatepe, Vildan, Sezgin, Derya Subaşı, Uras, Cihan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116476/ https://www.ncbi.nlm.nih.gov/pubmed/37079089 http://dx.doi.org/10.1007/s00520-023-07742-2

Ejemplares similares

Example of a Simulation Design in Nursing Education: Safe Chemotherapy Administration
por: Uslu, Yasemin, et al.
Publicado: (2019)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Tamoxifen in breast cancer survivors with COVID 19: stop or go?
por: Karacin, Cengiz, et al.
Publicado: (2021)

The Effect of Coffee in the Prevention of Oral Mucositis Associated with Head and Neck Radiotherapy
por: Kayikci, Emel Emine, et al.
Publicado: (2023)

Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review
por: Toivonen, Kirsti I., et al.
Publicado: (2020)

Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework
por: Moon, Zoe, et al.
Publicado: (2020)

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Publicado: (1988)

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors
por: Camacho, Fabian T., et al.
Publicado: (2017)

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis
por: Al-Mubarak, Mustafa, et al.
Publicado: (2014)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
por: Pistilli, Barbara, et al.
Publicado: (2020)

Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer
por: Giudici, Fabiola, et al.
Publicado: (2023)

Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen
por: Coradini, D, et al.
Publicado: (2003)

Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
por: Eisner, Alvin, et al.
Publicado: (2007)

Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
por: Abahssain, Halima, et al.
Publicado: (2010)

Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment
por: Rhee, Jiyoung, et al.
Publicado: (2014)

Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
por: Pinzón-García, Ana D., et al.
Publicado: (2021)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
por: Cruz, Aline, et al.
Publicado: (2017)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom
por: McGuinness, Serena, et al.
Publicado: (2022)

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.
Publicado: (1988)

Systematic adaptation of the adherence improving self‐management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach
por: Janssen, Anna M., et al.
Publicado: (2022)

Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer [Letter]
por: Bekele, Firomsa
Publicado: (2021)

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer
por: McCowan, C, et al.
Publicado: (2008)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
por: Baek, Soo Yeon, et al.
Publicado: (2019)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances
por: Yilmaz, Cengiz, et al.
Publicado: (2022)

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
por: Huang, Yu-Hsiang, et al.
Publicado: (2018)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study
por: Lee, Jihyoun, et al.
Publicado: (2020)

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Harrigan, Maura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u6mcj7gim9aium2kb4p2otdmv6